Physicochemical Properties
Molecular Formula | C14H21N3O5 |
Molecular Weight | 311.33 |
Exact Mass | 311.148 |
CAS # | 24697-74-3 |
Related CAS # | Leonurine hydrochloride;24735-18-0 |
PubChem CID | 161464 |
Appearance | White to off-white solid powder |
Density | 1.3±0.1 g/cm3 |
Boiling Point | 496.7±55.0 °C at 760 mmHg |
Melting Point | 191-193ºC |
Flash Point | 254.2±31.5 °C |
Vapour Pressure | 0.0±1.3 mmHg at 25°C |
Index of Refraction | 1.554 |
LogP | 0.22 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 9 |
Heavy Atom Count | 22 |
Complexity | 360 |
Defined Atom Stereocenter Count | 0 |
InChi Key | WNGSUWLDMZFYNZ-UHFFFAOYSA-N |
InChi Code | InChI=1S/C14H21N3O5/c1-20-10-7-9(8-11(21-2)12(10)18)13(19)22-6-4-3-5-17-14(15)16/h7-8,18H,3-6H2,1-2H3,(H4,15,16,17) |
Chemical Name | 4-(diaminomethylideneamino)butyl 4-hydroxy-3,5-dimethoxybenzoate |
HS Tariff Code | 2934.99.9001 |
Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
ln Vitro | Less lipid buildup, higher cellular cholesterol content (including total cholesterol (TC), free cholesterol (FC), and cholesteryl esters (CE), and apoA-I, or HDL-mediated cholesterol efflux, were the outcomes of leonurus alkaloids (0, 5, 10, 20, 40, and 80 µM) administration 24 hours later. In human THP-1 cells, lenurine can also dramatically and dose-dependently boost the mRNA and protein expression of ABCA1 and ABCG1, an action that is linked to PPARγ [1]. When palmitic acid (PA) is added as a free fatty acid (FFA) to HepG2 and HL-7702 cells for a whole day, leonurine hydrochloride (LH) protects the cells' survival. By triggering the AMPK/SREBP1 pathway, leonurineHCl (125, 250, and 500μM) enhances cellular lipid accumulation in HepG2 and HL-7702 cells [2]. In human chondrocytes, leonurine (5, 10, 20 µM) reduces the production of iNOS, COX-2, PGE2, NO, TNF-α, and IL-6 caused by IL-1β. It also inhibits the breakdown of extracellular matrix (ECM) in human OA chondrocytes. Furthermore, in a dose-dependent way, blocking IL-1β causes PI3K and Akt activation. |
ln Vivo | In mouse serum, motherwort (10 mg/kg/d) significantly increased the expression of PPARγ, LXRα, ABCA1, and ABCG1, while lowering the levels of TG and TC [1]. By stimulating the AMPK/SREBP1 pathway, motherwort hydrochloride (50, 100, or 200 mg/kg) decreases liver peroxidized lipids, increases antioxidant levels, and improves intracellular lipid accumulation in mice [2]. In an orthopaedic mouse model of DMM, motherwort (20 mg/kg) ameliorates the development of osteoarthritis [3]. |
References |
[1]. Leonurine Prevents Atherosclerosis Via Promoting the Expression of ABCA1 and ABCG1 in a Pparγ/Lxrα Signaling Pathway-Dependent Manner. Cell Physiol Biochem. 2017;43(4):1703-1717. [2]. Novel hepatoprotective role of Leonurine hydrochloride against experimental non-alcoholic steatohepatitis mediated via AMPK/SREBP1 signaling pathway. Biomed Pharmacother. 2018 Dec 7;110:571-581. [3]. Inhibition of PI3K/Akt/NF-κB signaling with leonurine for ameliorating the progression of osteoarthritis: In vitro and in vivo studies. J Cell Physiol. 2018 Nov 11. |
Additional Infomation |
Leonurine is a trihydroxybenzoic acid. Leonurine has been reported in Leonurus sibiricus and Leonotis leonurus with data available. |
Solubility Data
Solubility (In Vitro) |
DMSO : ~33.33 mg/mL (~107.06 mM) H2O : ~1 mg/mL (~3.21 mM) |
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300:Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.2120 mL | 16.0601 mL | 32.1203 mL | |
5 mM | 0.6424 mL | 3.2120 mL | 6.4241 mL | |
10 mM | 0.3212 mL | 1.6060 mL | 3.2120 mL |